Murnac-tripeptide (BioDeep_00000181144)
human metabolite blood metabolite
代谢物信息卡片
化学式: C26H44N6O14 (664.2915364)
中文名称:
谱图信息:
最多检出来源 Homo sapiens(blood) 95.45%
分子结构信息
SMILES: CC(C(=O)NC(CCC(=O)NC(CCCC(C(=O)O)N)C(=O)O)C(=O)N)NC(=O)C(C)OC(C(C=O)NC(=O)C)C(C(CO)O)O
InChI: InChI=1S/C26H44N6O14/c1-11(29-24(41)12(2)46-21(20(38)18(36)10-34)17(9-33)30-13(3)35)23(40)32-15(22(28)39)7-8-19(37)31-16(26(44)45)6-4-5-14(27)25(42)43/h9,11-12,14-18,20-21,34,36,38H,4-8,10,27H2,1-3H3,(H2,28,39)(H,29,41)(H,30,35)(H,31,37)(H,32,40)(H,42,43)(H,44,45)
描述信息
同义名列表
7 个代谢物同义名
2-amino-6-[4-carbamoyl-4-(2-{2-[(2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl)oxy]propanamido}propanamido)butanamido]heptanedioic acid; N-Acetylmuramyl-alanyl-isoglutaminyl-meso-2,2-diaminopimelic acid; N-Acetylmuramyl-L-alanyl-D-isoglutaminyl-L-lysine; AcMu-ala-iso-GLN-2,2-diaminopimelic acid; Ac-mur-L-ala-gamma-D-GLN-meso-a(2)PM; MuramylNAc-ala-isogln-lys-tripeptide; Murnac-tripeptide
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- E G MacEwen, I D Kurzman, D M Vail, R R Dubielzig, K Everlith, B R Madewell, C O Rodriguez, B Phillips, C H Zwahlen, J Obradovich, R C Rosenthal, L E Fox, M Rosenberg, C Henry, J Fidel. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
Clinical cancer research : an official journal of the American Association for Cancer Research.
1999 Dec; 5(12):4249-58. doi:
". [PMID: 10632367] - F Gaytan, C Bellido, C Morales, M García, N van Rooijen, E Aguilar. In vivo manipulation (depletion versus activation) of testicular macrophages: central and local effects.
The Journal of endocrinology.
1996 Jul; 150(1):57-65. doi:
10.1677/joe.0.1500057. [PMID: 8708563] - I D Kurzman, E G MacEwen, R C Rosenthal, L E Fox, E T Keller, S C Helfand, D M Vail, R R Dubielzig, B R Madewell, C O Rodriguez. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research.
1995 Dec; 1(12):1595-601. doi:
". [PMID: 9815961] - P De Pauw, C Neyt, E Vanderwinkel, R Wattiez, P Falmagne. Characterization of human serum N-acetylmuramyl-L-alanine amidase purified by affinity chromatography.
Protein expression and purification.
1995 Jun; 6(3):371-8. doi:
10.1006/prep.1995.1049. [PMID: 7663175] - S Nagao, Y Kawabata, M Kitano, K Suzuki, T Nishikawa, H Takada. Modification of delayed-type hypersensitivity reactions by muramyldipeptide in guinea pigs.
FEMS immunology and medical microbiology.
1995 Jun; 11(3):231-45. doi:
10.1111/j.1574-695x.1995.tb00121.x. [PMID: 7581275] - D Favaro, M Santarosa, M Quaia, A Spada, A Freschi, R Talamini, E Galligioni. Soluble intercellular adhesion molecule-1 and serum cytokines in melanoma patients treated with liposomes containing muramyl tripeptide.
Tumori.
1995 May; 81(3):185-90. doi:
10.1177/030089169508100306. [PMID: 7571025] - E Galligioni, M Quaia, A Spada, D Favaro, M Santarosa, R Talamini, S Monfardini. Activation of cytolytic activity in peripheral blood monocytes of renal cancer patients against non-cultured autologous tumor cells.
International journal of cancer.
1993 Sep; 55(3):380-5. doi:
10.1002/ijc.2910550307. [PMID: 8375921] - F Shi, E G MacEwen, I D Kurzman. In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation.
Cancer research.
1993 Sep; 53(17):3986-91. doi:
NULL. [PMID: 8358727] - E S Kleinerman, A K Raymond, C D Bucana, N Jaffe, M B Harris, I H Krakoff, R Benjamin, I J Fidler. Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid).
Cancer immunology, immunotherapy : CII.
1992; 34(4):211-20. doi:
10.1007/bf01741788. [PMID: 1537053] - W E Fogler, R Wade, D E Brundish, I J Fidler. Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice.
Journal of immunology (Baltimore, Md. : 1950).
1985 Aug; 135(2):1372-7. doi:
NULL. [PMID: 4008926] - E S Kleinerman, K L Erickson, A J Schroit, W E Fogler, I J Fidler. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide.
Cancer research.
1983 May; 43(5):2010-4. doi:
NULL. [PMID: 6831430] - A Yapo, J F Petit, E Lederer, M Parant, F Parant, L Chedid. Fate of two 14C labelled muramyl peptides: Ac-Mur-L-Ala-gamma-D-Glu-meso-A2pm and Ac-Mur-L-Ala-gamma-D-Glu-meso-A2pm-D-Ala-D-Ala in mice. Evaluation of their ability to increase non specific resistance to Klebsiella infection.
International journal of immunopharmacology.
1982; 4(3):143-9. doi:
10.1016/0192-0561(82)90042-x. [PMID: 7049971]